Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
TATakeda Pharmaceutical Company Limited logo

Takeda Pharmaceutical Company Limited (TAK)

New York Stock Exchange · Currency in USD
$20.24 ▼ -0.12 (-0.59%)
At close: Oct 23, 4:00 PM ET. Market closed.

Summary

Previous Close
$20.36
Open
$20.28
Day's Range
$20.17 – $20.34
52 Week Range
$12.99 – $20.39
Volume
2,099,176
Avg. Volume
2,979,841
Market Cap
$64.41B
Beta (5Y Monthly)
0.09
PE Ratio (TTM)
55.94
EPS (TTM)
$57.83
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
$0.79 (3.92%)
Ex-Dividend Date
Sep 29, 2026
1y Target Est
--

Profile: Takeda Pharmaceutical Company Limited

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
47,029
CEO
Julie So-Young Kim
Website
takeda.com

Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate $0.15 · Revenue est. $7.34B
DateEst.Actual
Jul 30, 2026$0.17$0.23Beat
May 13, 2026$0.21-$0.05Miss
Jan 29, 2026$0.55$0.21Miss
Oct 30, 2025$0.44-$0.02Miss
Jul 30, 2025$0.47$0.52Beat
May 8, 2025$0.24-$0.22Miss

Analyst view

Rating: Buy
Buy 83% · Hold 17% · Sell -0%

Get free alerts on TAK and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.